200 related articles for article (PubMed ID: 38656685)
21. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
Nowakowski GS; Feldman T; Rimsza LM; Westin JR; Witzig TE; Zinzani PL
Blood Cancer J; 2019 May; 9(6):48. PubMed ID: 31097684
[TBL] [Abstract][Full Text] [Related]
22. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.
Melani C; Wilson WH; Roschewski M
Best Pract Res Clin Haematol; 2018 Sep; 31(3):285-292. PubMed ID: 30213398
[TBL] [Abstract][Full Text] [Related]
23. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
24. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
[TBL] [Abstract][Full Text] [Related]
25. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
27. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Application and Research Progress of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Zhang HY; Yang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1917-1921. PubMed ID: 36476926
[TBL] [Abstract][Full Text] [Related]
29. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
[TBL] [Abstract][Full Text] [Related]
30. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
31. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
Heger JM; d'Hargues Y; Kleinert F; Mattlener J; Weiss J; Franzen F; Becker C; Becker K; Gödel P; Schmiel M; Meinel J; Flümann R; Simon F; Reinhardt HC; Borchmann P; Borchmann S; Balke-Want H; Knittel G; von Tresckow B
Eur J Haematol; 2024 Jun; 112(6):957-963. PubMed ID: 38369814
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
Lakhotia R; Roschewski M
Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
35. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
37. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy in hematological malignancies: current and future applications.
Talotta D; Almasri M; Cosentino C; Gaidano G; Moia R
Front Oncol; 2023; 13():1164517. PubMed ID: 37152045
[TBL] [Abstract][Full Text] [Related]
39. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
40. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
